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ASD and epilepsy, two common co-occurrent conditions, may appear in a 
developing brain in various genetic and non- genetic syndromes. The fact that 
multiple genetic and epigenetic factors, metabolic diseases, environmental factors 
and epileptic encephalopathies are related to the causation of both ASD and epi-
lepsy indicate the presence of some common underlying pathophysiologic mecha-
nisms. Although many questions are yet to be answered, recent studies suggest 
that synaptic aberrant connectivity and disruption of the delicate balance between 
neuronal excitation and inhibition (E/I imbalance) leads to various aspects of neu-
ronal dysfunction. The presence of intellectual disability increases the likelihood of 
co-morbid ASD and epilepsy and all these associations greatly affect the quality of 
life of these children as well as their families. Therefore, understanding the genetic, 
cellular and molecular basis of relationship between these common co-morbid 
conditions is fundamental in planning appropriate and prompt management of 
these children. Future researches will as such continue to address the pathophysiol-
ogy underlying the genetic, chromosomal, metabolic-mitochondrial disorders and 
environmental factors related to these co-morbidities as well as preventing them. 
Thus, it will lay the base of focused investigations and targeted management in 
this field.
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1. Introduction
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder 
characterized by deficits in social-communication interaction and restricted and 
repetitive behaviors [1]. It covers a wide variation in clinical presentation, symptom 
severity, and cognitive ability. These symptoms are present from early years of life.
Epilepsy is characterized by an enduring tendency to produce epileptic seizures 
and practically defined as having two untriggered seizures occurring at least 
24 hours apart [2]. Associated comorbidities are very common in ASD. Among 
them, epilepsy is an important medical condition that could affect the lives of per-
sons with ASD. Kanner’s original paper in 1943 describing 11 children with “autistic 
disturbances of affective contact,” included one child with history of seizures and 
abnormal electroencephalogram (EEG) [3]. Since then, the relationship of autism 
to epilepsy has been an area of interest for scientists for decades.
Association between autism and epilepsy has now been recognized and well 
established. Prevalence of epilepsy in autism ranged from 5–46% in quite a large 
number of studies [4–10] which exceeds than that of the general population 
Autism Spectrum Disorder - Profile, Heterogeneity, Neurobiology and Intervention
2
(0.6–1%) [11–12]. This wide range is likely due to heterogeneity of groups being 
studied, particularly with regard to cognitive functioning of the participants, 
sample age range, sex and inclusion or exclusion of other co-occurring medical 
conditions [8].
In addition, methodological differences used for diagnosing ASD also lead to 
these differences in prevalence rate. In the earlier studies, only severe autism associ-
ated with a high rate of intellectual disability (ID) and a high rate of epilepsy were 
included, whereas more recent studies that have used the current broader “ASD” 
criteria (DSM-5) might lead to a lower rate of ID and a lower rate of epilepsy.
Several factors have been associated with a greater risk for developing epilepsy. 
Among them, ID is the single most common risk factor. Amiet et al., in a meta-
analysis on epilepsy in autism encompassing articles from 1963–2006 demonstrated 
a relationship between epilepsy in autism with ID and gender. Here epilepsy was 
present in 21.5% of subjects with autism who also had ID and 8% of subjects 
without ID [9].
Previous studies in the ASD population have found that idiopathic ASD (i.e., no 
known cause) had a lower risk of developing epilepsy than those with syndromic 
autism (i.e., associated with underlying neural/genetic abnormalities) [13]. Pavone 
et al. found epilepsy in only 7.4% with idiopathic ASD compared to 55% of patients 
with syndromic ASD [14]. These findings match with the hypothesis that one 
abnormal neural dysfunction may make the brain more susceptible to another 
neurological dysfunction [15]. This also supports the hypothesis that epilepsy, 
ID and ASD may all be the result of a mutual underlying neurological condition. 
Equally, children with epilepsy also have an increased risk for being diagnosed 
with ASD [8, 16].
Besides, on average, autistic adults with epilepsy have, less cognitive ability and 
weaker daily living skills than their autistic peers who do not have seizures [17, 18]. 
There is also a strong influence on the quality of life and well-being in children with 
epilepsy.
Because of these facts, clinicians and researchers have worked to understand 
how epilepsy and ASD can relate to each other. Studying the two disorders in com-
bination may help in understanding their genetic, molecular, and cellular mecha-
nisms that are critical in the field of appropriate management of the both [19, 20].
2. Age of onset of epilepsy
Differing results have been found regarding the age of onset of epilepsy in ASD. 
Most of the researchers found seizure onset during early childhood [5, 21, 22]. 
However, Bolton et al. in a long-term follow-up study of 150 individuals with autism, 
found epilepsy onset in the majority of cases over 10 years and some in adulthood 
[7], this also agrees with few other studies [6, 23]. While others found, two peaks in 
the age distribution of seizure onset in autism, one in early childhood and a another 
in adolescence [13, 24]. Epilepsy persists in adulthood in up to 80%, with remission 
in about 16% in ASD.
3. Sex
Reports have suggested that females with autism have higher rates of epilepsy than 
males [6, 8, 13, 16, 22, 25, 26]. Amiet’s study reported prevalence of epilepsy, in autistic 
females 34.5% versus 18.5% in autistic males [9]. Studies have reported a more fre-
quent association of epilepsy in persons with ID than without ID [6, 9]. Since females 
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with autism tend to have more severe ID compared to males [9, 27], greater ID severity 
might be a possible cause for this high prevalence of epilepsy in autistic females [28].
4. ID and epilepsy in autism
Intellectual disability (ID), referring to general intelligence and adaptive func-
tioning below −2 standard deviations for population norms, occurs in about 38% of 
children with ASD [29].
A key concept that has developed during the past 40 years is the strong asso-
ciation between intellectual disability and a higher prevalence of epilepsy in 
individuals with ASD [25]. Amiet et al. carried out a meta-analysis from published 
reports between 1963 and 2006 on autism and epilepsy to assess the relative risk of 
epilepsy in autism with respect to ID [9]. The pooled prevalence of epilepsy with 
and without ID was highly significant (21.5% versus 8% respectively). This study 
also highlighted on the association of increasing ID severity on the prevalence of 
epilepsy in autism [9, 30].
Other authors also have argued that intelligence mediates the relationship 
between autism and epilepsy [17, 26, 30–34], and lower the intellectual ability, the 
higher the prevalence of epilepsy and autism. According to Viscidi et al. al, low IQ 
is the best predictor of epilepsy in children and also commented that the presence 
of ID can guide prognosis and alert physicians regarding who are at increased risk 
for epilepsy [6]. A recent study on 6975 children by Jasua et al. with ASD found ID 
alone as an independent predictor for the increased prevalence of epilepsy [19, 20].
The high rate of co-occurrence of ID, epilepsy and ASD suggests potentially 
shared underlying mechanisms. All three could result from the same pathophysi-
ologic mechanisms. Therefore, it may be more likely to occur in genetic conditions 
that lead to abnormal excitability and disrupted synaptic plasticity, such as fragile 
X syndrome, neuroligin 2 mutations, Rett syndrome, tuberous sclerosis complex, 
cyclin-dependent kinase-like 5 (CDKL5) mutations, and “interneuronopathies” 
resulting from aristaless-related homeobox, X-linked (ARX), all of which include 
ASDs, IDs, and epilepsy [35].
5. Etiology and pathogenesis
The high co-occurrence of autism and epilepsy has led to the speculation that 
there are some common mechanisms linking these two types of disorders. But a 
singular pathophysiological mechanism responsible for the seizures and autistic 
phenotype is unlikely. Scientists have stressed mainly upon the genetic factors as the 
most common contribution for this co-occurrence followed by environmental and 
metabolic conditions.
Buckley and Holmes have conceptualized ASD and epilepsy both as disorders of 
aberrant connectivity caused by multiple genetic and environmental factors [36]. 
Chromosomal abnormalities [37], metabolic conditions [38, 39], environmental 
factors, e.g., maternal rubella during pregnancy [40], and brain damage via neona-
tal jaundice are examples that have been recognized as predisposing to both epilepsy 
and autism [41].
5.1 Genetic factors and syndromes
ASD and epilepsy are both described in various genetic syndromes, which 
includes single and common gene mutations as well as undiscovered rare mutations 
Autism Spectrum Disorder - Profile, Heterogeneity, Neurobiology and Intervention
4
and copy number variations [36, 42]. Both ASD and epilepsy can be understood as 
disorders of synaptic plasticity, where the same pathological mechanisms result in 
developmental imbalances of excitation and inhibition in the developing brain.
This genetically-derived abnormal plasticity can result in both ASD and epi-
lepsy. Examples are fragile X, Rett syndrome, tuberous sclerosis complex (TSC), 
CDKL5 mutations, neuroligin mutations, “interneuronopathies” that results from 
X-linked aristaless-related homeobox (ARX) and Neuropilin 2 (NRP2) gene muta-
tions. Moreover, the process of epileptogenesis and/or spontaneous seizures may 
result in maladaptive synaptic plasticity and produce imbalances of excitation and 
inhibition. All these processes might contribute to behavioral and learning difficul-
ties. Alterations in receptors, signaling molecules or neurotropins may also result in 
synaptic abnormalities. Early-life seizures due to genetic conditions may be associ-
ated with both ASD and epilepsy (Figure 1).
Synaptic plasticity is the process whereby, the connections between 2 neurons of 
the synapses, get strengthened by experiencing or practicing. When these connec-
tions (i.e., synapses) are activated, AMPA receptors mediated by depolarization 
blocks release of magnesium and helps in entry of calcium through the NMDA 
receptors. This stimulates calcium dependent activation of kinases and other 
signaling pathways and enhances gene transcription and trafficking of receptors. 
This results in faster and stronger synaptic connections. This is known as long-term 
Figure 1. 
Abnormal excitability and disrupted synaptic plasticity in the developing brain result in both ASD and 
Epilepsy. This abnormal plasticity can result from different genetic conditions. Early life seizures during early 
post-natal development may also alter synaptic plasticity and results in ASD. Mechanisms lie in alterations in 
receptors, signaling molecules or neurotrophins.
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potentiation and, is believed be the cellular basis of learning. In some of the genetic 
conditions associated with autism and epilepsy, variety of genes are disrupted upon 
which synaptic plasticity depends. These include cyclin-dependent kinase-like 5 
(CDKL5) in West syndrome, MeCP2 in Rett syndrome, FMRP in fragile X mental 
retardation syndrome, mTOR in tuberous sclerosis, and reelin in lissencephaly.
Knowledge of copy number variation and single gene disorders that are dis-
turbed in these two developmental disorders include gene transcriptional regula-
tion; cellular growth and proliferation; and synapse development, stability, and 
function. An overview of biological common pathway of ASD and epilepsy are 
shown in Figure 2.
5.1.1 Single gene disorders
5.1.1.1 Fragile X syndrome
Fragile X syndrome (FXS) is the most frequent form of genetic disorder causing 
ID and often presents with ASD and epilepsy. It occurs when a triplet repeat (CGG) 
expansion leads to inactivation of the FMR1 gene which is responsible for coding of 
FMRP- fragile X mental retardation protein. FMRP is associated with and regulates 
various mRNA related to development and functions of dendritic spines, axons and 
synapses, formation and wiring of neuronal circuits and plasticity of brain. It also 
regulates metabotropic glutamate receptor (mGluR)-induced long-term depres-
sion (LTD). As the “mGluR theory of fragile X” postulates that FMRP and group I 
metabotropic glutamate receptors (mGluRs) play oppositional roles at the level of 
synaptic function, loss of FMRP function and activation of mGluRs lead to exces-
sive AMPA receptor internalization, exaggerated LTD and therefore, disrupted 
synaptic activity. Bianchi et al. provided compelling evidence that a voltage-gated 
Figure 2. 
Four important biological pathways for neuronal development and function common to autism spectrum 
disorder and epilepsy, that includes transcriptional regulation (FOXG1, MECP2 and MEF2C), cellular growth 
(PTEN, TSC1, and TSC2), synaptic channels (SCN2A), and synaptic structure (CASK, CDKL5, FMR1, and 
SHANK3).
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inward current, ImGluR (V), is the cellular basis for the epileptogenic behavior 
induced by activation of the mGluR5 receptor [43, 44]. In addition, dysregula-
tion of glutamergic neurons in FXS can disrupt the normal actions of inhibi-
tory GABAergic neurons, and downregulation of GABA receptor subunits and 
altered expression of a number of enzymes involved in the metabolism of GABA. 
Identification of this mechanism could contribute to hyperexcitability and epilepsy 
in the fragile X syndrome [45].
Physical features include prominent ears, long face, macrocephaly, and macroor-
chidism. The cognitive profile includes hyperactivity, anxiety, tactile defensiveness, 
gaze avoidance, and socialization difficulties. Epilepsy is reported in approximately 
10–20% of individuals with FXS [46]. Seizure patterns in FXS typically resemble 
benign focal epilepsy of childhood (BFEC). Moreover, 23% of individuals with FXS 
without clinical seizures demonstrated centrotemporal spikes on EEG.
5.1.1.2 Tuberous sclerosis complex
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that results 
from mutations in the TSC1 or TSC2 genes [47]. Although skin, kidney, heart, 
eye, and lung can be affected, involvement of the brain is associated with most 
significant morbidity. Central nervous system is consistently involved, with 90% of 
individuals affected showing structural abnormalities, and almost all having some 
degree of CNS clinical manifestations [48].
TSC1 and TSC2 genes, found in chromosomes 9 and 16, are responsible for 
encoding two proteins namely hamartin and tuberin respectively. They bind 
together to form a protein complex which in turn regulates the mammalian target of 
rapamycin (mTOR). The loss of function mutation in either of the two genes results 
in overactivity in mTOR signaling cascade with consequent disinhibition of protein 
synthesis and cell growth. A simplified diagram in Figure 3 shows the activation 
of mTOR cascade [48]. This shows the underlying brain dysfunction resulting in 
susceptibility to epilepsy, autism and cognitive impairment.
Cortical tubers constitute the hallmark of the disease and are pathognomonic of 
cerebral TSC. The number and localization of cortical tubers may account for the 
variability of the neurological phenotype observed in TSC patients [49]. Autism 
appears to be more common in infants with frontal and temporal tubers, and it has 
been suggested that an early dysfunction in the associative areas owing to the loca-
tion of cortical tuber may be responsible for the autistic features [49]. Tuberin, the 
product of TSC2 gene is expressed to a large extent in frontal and temporal regions 
of brain- the areas that are responsible for the behavioral phenotypes of the autistic 
disorder [50].
Epilepsy is the most common presenting symptom in tuberous sclerosis com-
plex. In up to 80% to 90% of persons with TSC, seizures will develop during their 
lifetime, with the onset most frequently in childhood. Approximately one-third 
develop infantile spasms. Almost all seizure types can be seen in persons with 
tuberous sclerosis complex, including tonic, clonic, tonic–clonic, atonic, myo-
clonic, atypical absence, partial, and complex partial. Only “pure” absence seizures 
are not observed [51].
Epilepsy in TSC is often medically intractable. The treatment of seizures in 
TSC is often difficult but efficacy of Vigabatrin in children has proved to have best 
results.
Although mutations in both TSC1 and TSC2 are associated with development 
of autism, TSC2 mutation has greater likelihood of developing ASD [52]. Again, 
early-onset and difficult to control infantile spasms, especially if there is an epi-
leptic focus in a temporal lobe, carry an increased likelihood of getting ASD in a 
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child. Because early onset of infantile spasms and associated hypsarrhythmia may 
have a malignant effect on brain development in infants with TSC, the importance 
to search for ways to anticipate the onset of infantile spasms before they become 
apparent as seizures is very important [53].
Rapamycin normalizes the dysregulated mTOR pathway, and recent clinical 
trials have demonstrated its efficacy in various TSC manifestations, suggesting the 
possibility that rapamycin may have benefit in the treatment of TSC brain disease.
5.1.2 PTEN
PTEN is a tumor suppressor gene that encodes a phosphatase affecting G1 
cell cycle arrest and inhibiting the PI3K–AKT–mTOR pathway, which has roles in 
controlling cell growth, survival and proliferation [54, 55]. ASD and macrocephaly 
and have been reported in children with germline PTEN mutations. PTEN-related 
Figure 3. 
Schematic representation of the potential roles of mTOR overactivation in determining the neurological and 
neuropsychiatric manifestations of tuberous sclerosis. (A) mTOR overactivation can dysregulate the balance 
between neuronal excitation and inhibition, leading to epileptogenesis. (B) mTOR overactivation can alter 
synaptogenesis and synaptic pruning, connectivity, and long-term potentiation, leading to an increased 
susceptibility to autism or intellectual disability, or both. mTOR=mammalian target of rapamycin. Courtesy 
of: Curatolo P, Moavero Vries P J. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. 
Lancet Neurol 2015; 14: 733–45.
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ASD is, therefore, emerging as one of a group of megalencephaly disorders associ-
ated with dysregulation of the PI3K–AKT–mTOR pathway [56]. In patients with 
PTEN mutations, seizures have been reported, in whom focal cortical dysplasia has 
also been reported [57]. Epilepsy seems to be a part of the phenotype for many of 
the megalencephaly disorders that are associated with impaired regulation of the 
PI3K–AKT–mTOR pathway [56] but the exact roles of mutations in these specific 
genes with and their relation to seizures and ASDs are not clarified.
5.1.2.1 MECP2-related disorder (Rett syndrome)
MECP2-related disorder, result of an X- linked loss- of- function mutation of 
MECP2, starts presenting with regression typically at 6 to 18 months of age after 
a period of apparently normal development. Females are predominantly affected 
with this disorder which is manifested with ID, postnatal microcephaly, loss of 
spoken language, and stereotypic hand movements. Besides autistic symptoms 
individuals with MECP2-related disorder may present other symptoms like respira-
tory rhythm abnormalities, gait impairment, and cardiac complications as well. 
Approximately 50–90% of children are reported to have seizures, the type of which 
is variable [58]. The age of onset of seizure is rarely before 2 years of age, and the 
severity appears to decline after adolescence.
MeCP2 acts, at least in part, as a transcriptional repressor during brain devel-
opment. And it may be required to reduce aberrant transcriptional events, thus 
allowing the transcriptional machinery to function efficiently. In addition, it has 
been suggested to have a function in synaptogenesis or maintenance of neuronal 
function. The onset of Rett syndrome at 6 to 18 months, coincides with a period of 
widespread synaptogenesis in the human brain [59], which is compatible with the 
view that RTT could be caused by failure to form synapses appropriately. Evidence 
supporting a role for MeCP2 in synapse formation includes altered glutamatergic 
synapse numbers in vitro and in vivo and changes to neuronal morphology in some 
brain regions. These findings suggest that long-term changes occur in neuronal 
networks in the MeCP2-deficient brain [60].
5.1.2.2 CDKL5-related disorder
CDKL5-related disorders are X-linked condition, manifest early in life with 
epilepsy, usually infantile spasms, postnatal microcephaly and severe neurodevel-
opmental problems. Girls with mutations in CDKL5 display various ASD features 
including abnormal social interactions, repetitive movements, and absent speech. 
However, the developmental disability and the epilepsy phenotype associated with 
this condition are much greater than those typically seen in children with classical 
forms of ASD.
CDKL5 is a key-limiting factor in regulating synapse formation. To exert its 
role CDKL5 binds and phosphorylates the cell adhesion molecule NGL-1. This 
phosphorylation event ensures a stable association between NGL-1 and PSD95 (key 
candidates in ASD pathogenesis) in glutamatergic post synapses during dendrite 
spine development and generates significant role in stabilizing the postsynaptic 
membrane [61].
5.1.2.3 FOXG1-related disorders
FOXG1-related disorders are associated with epilepsy, severe ID, absent speech 
with autistic features. Children may present with duplications on chromosome 
14q12 or mutations of FOXG1. Children with duplication of 14q12 often present 
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with infantile spasm followed by ID with autistic features [62]. These patients may 
also present postnatal microcephaly, morphologic abnormalities of corpus callosum 
and choreiform movements. The mean age at epilepsy onset for children with dele-
tions/loss-of function mutations of FOXG1 is 22 months. FOXG1 is a brain-specific 
transcriptional repressor protein that regulates neurogenesis.
5.1.2.4 MEF2C-related disorder
These are extremely rare genetic disorder caused by a in the MEF2C gene. This 
mutation, often a deletion, leads to the dysfunction of MEF2C protein which is 
essential to the proper functioning of the neurological system in addition to other 
systems.
Patients with mutations and deletions of MEF2C on chromosome 5q14.3 may 
present with severe ID, epilepsy, and stereotypic movements. Autistic features 
have been recognized with some overlap with features found in MECP2-related 
disorder with a very small deletion encompassing the MEF2C gene [63]. This The 
epilepsy found in individuals with MEF2C-related disorder can be variable, with 
20% presenting with infantile spasms, 33% presenting with infant-onset myoclonic 
epilepsy, 24% presenting with childhood onset generalized epilepsy. MEF2C is 
essential for early neurogenesis, neuronal migration and differentiation.
5.1.2.5 CASK-related disorders
CASK-related disorders are genetically defined neurodevelopmental syndromes 
that includes ASD, ID, ADHD as well as epilepsies. CASK encodes for calcium/
calmodulin-dependent serine protein kinase (CASK), located on chromosome 
Xp11.4, in which pathogenic variants underlie a range of NDDs.
Mutations affecting CASK were first described in cases with microcephaly 
with pontine and cerebellar hypoplasia (MICPCH), followed by the identifica-
tion in cases with X-linked ID (XL-ID), developmental delay (DD), and ASD. But 
ASD diagnosis here is difficult because of the presence of the severity of impair-
ment and ID.
CASK is expressed with high expression in the developing human brain and has 
a role in synapse formation and cortical development. Reduced CASK protein levels 
affect presynaptic development and decrease inhibitory pre-synapse size, which 
might have consequences to E/I balance in developing neural circuitries. Aberrant 
E/I balance, and synaptogenesis are two common biological pathways that underlies 
the NDDs of different genetic origin.
5.1.2.6 Other conditions with genetic abnormalities
There are few syndromes which are not always present with autism and 
epilepsy both. But where, genetic mutation in combination with environmental 
risk factors can result in the appearance of autism and epilepsy. The responsible 
genes are CNTNAP2, RELN, SYNGAP1, SYN1, NRXN1, BCKDK, RBFOX1 and 
SCN1A, SCN2.
5.1.3 Genomic copy number variants
5.1.3.1 15q11-q13 duplication syndrome
15q11-q13 duplication syndrome is characterized by developmental delay (DD), 
epilepsy, and autism.
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Individuals with this syndrome have features of both PWS and AS which are 
caused by deletions spanning this region. Muscle hypotonia is observed in almost all 
individuals with Dup15q syndrome, and can be severe. ID and feeding difficulties 
are common. Joint hyperextensibility and drooling accompanies the hypotonia in 
most individual.
Seizures affect approximately 60% of children with Dup15q syndrome, with the 
typical onset occurring before age 5 years. A high incidence of infantile spasm with 
later progression to Lennox–Gastaut syndrome (LGS) has also been reported [64]. 
However, multiple seizure types including tonic, atonic, tonic–clonic, myoclonic, 
complex partial, and atypical absence have also been reported. These seizures can 
be intractable.
A majority of individuals with Dup15q syndrome meet the diagnostic criteria for 
autism. Expressive language is typically severely impacted, and may even be absent. 
Behavioral difficulties like ADHD, anxiety, and frustration leading to tantrums are 
sometimes associated in some affected individuals.
Dup15q syndrome is caused by presence of at least one extra maternally derived 
copy of the Prader-Willi/Angelman critical region (PWACR) within chromo-
some 15q11.2-q13.1. Duplications may vary in size but must contain the PWACR 
to be causative of dup15q syndrome. This duplicated region encodes for GABRA5, 
GABRB3, and GABRG3 of the GABA receptor subunit allow one to hypothesize the 
inhibitory-synapses mediated dysregulation as the pathogenesis of the epilepsy and 
ASD phenotypes found in this disorder [65].
5.1.3.2 Trisomy 21 (Down syndrome)
Trisomy 21 or Down syndrome (DS) is a genetic condition in which a child is 
born with an extra copy of their 21st chromosome. It is usually associated with 
characteristic facial features, mild to moderate ID, and few associated congenital 
anomalies. Previous thinking held that autism is rare in DS. But the fact is that, it 
is estimated that autism in individuals with Down syndrome is 10–25 times more 
common than in the typical population [66]. However, this diagnosis often comes 
much later than it would for an otherwise typical child. This might be due to the 
presence of associated ID. The prevalence of epilepsy in patients with DS is approxi-
mately 1–13%. Infantile spasm (IS) is most frequently found seizure and represents 
4.5–47% of these children [67]. Lennox–Gastaut syndrome (LGS), reflex seizures 
and others such as partial and generalized tonic clonic seizures have also been 
described in children with DS. A high rate of EEG abnormalities has been reported 
in DS, even among children without epilepsy [67].
Important mechanisms of epileptogenesis in DS are due to alteration of neuronal 
or synaptic anatomy resulting from fewer inhibitory inter-neurons, decreased 
neuronal density and membrane channel dysfunction due to altered membrane 
potassium permeability, decreased voltage threshold for spike generation.
5.1.3.3 Other copy number variants (CNVs)
Certain pathogenic copy number variants are highly associated with ASD and 
epilepsy. Deletions of 15q11.2, 16p11.2, and duplication of 16p13.11 have been 
detected with high frequency in individuals with ASD [68].
5.1.3.4 Phelan–McDermid syndrome (22q13 deletion syndrome)
Phelan-McDermid syndrome (PMS) is a rare genetic condition caused by dele-
tion of 22q13.3 containing the SHANK3 gene. The genetic changes that cause PMS 
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vary from person to person and so do the clinical features. PMS can appear de novo 
or be inherited from a parent (20%) who carries a related genetic defect. A broad 
spectrum of medical, intellectual and behavioral challenges can arise from the 
symptoms of PMS; however, ID at varying stages, delayed or absent speech, motor 
delays, low muscle tone, symptoms of ASD and epilepsy have been found to be 
some of the most regularly observed traits of people with PMS. Some have reported 
a benign course of generalized tonic–clonic or myoclonic seizures with typical EEG 
features.
Current research specifies the inability of the single functioning copy of 
SHANK3 to produce sufficient Shank3 protein for normal functioning. This 
may be responsible for most of the neurologic symptoms associated with this 
disorder. A larger series found seizures to be three times more common when 
the de novo deletion occurred on the maternally rather than paternally inherited 
chromosome 22 [69].
5.2 Environmental and epigenetic
5.2.1 Environmental fctors
Although genetic factors are clearly involved in ASD risk, they cannot fully 
account for all the cases. It is likely that a combination of autism-related genes 
and specific environmental factors might act as risk factors that triggers the 
development of autism. A population-based case–control study done in India 
found several environmental factors for example, the living conditions of fam-
ily members, infection during pregnancy and preeclampsia, that could trigger 
development of the autism disorder [70]. Schmidt 2014 reviewed the environ-
mental factors associated with autism, some of which may also be associated 
with epilepsy [71]. They reported consistent results for an association of higher 
maternal intake of certain supplements with reduction in ASD risk, with the 
strongest evidence for folic acid supplements [71, 72]. If a mother is exposed to 
a relevant environmental toxin and her offspring has a genetic predisposition, 
the combined effect might result in development of ASD, and carries a risk of 
epilepsy as well.
Intrauterine infection, e.g., maternal rubella during pregnancy has long been 
associated with a high risk of ID, autism and epilepsy in the offspring [40]. Use 
of antiepileptic drug sodium valproate during pregnancy can also affect brain 
development of the fetus, leading to ID and autism [71]. Rybakowski et al., empha-
sized that factors occurring already before conception like age of the parents, 
family autoimmune factors and maternal metabolic factors like obesity, diabetes, 
hypertension play important roles [72]. Many authors reported of factors occur-
ring during pregnancy, such as bleeding throughout the pregnancy, multiple 
pregnancy, intrauterine infections (TORCH, bacterial, other) and maternal hypo-
thyroidism. Arterial hypertension during pregnancy seems important, along with 
pre-eclampsia and eclampsia, severe anemia, smoking during the pregnancy [71, 
73], maternal stress during pregnancy etc. Among other factors preterm delivery, 
low birth weight, intrauterine growth retardation and hypoxic ischaemic encepha-
lopathy are mentioned. Among neonatal factors, the most commonly mentioned 
are: intraventricular bleeding, hyperbilirubinemia and congenital defects. While 
all these are responsible for development of ASD, more research is needed to know 
the association of epilepsy in these cases. However, environmental risk factors do 
not solely cover the exposure to toxins but include all changes other than those on a 
DNA–level, such as maternal nutrition, infection during pregnancy, and prematu-
rity as well as parental age at conception.
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5.3 Metabolic disorders associated with epilepsy in ASD
Many metabolic disorders may be associated with ASD and epilepsy. Among 
them, conditions like mitochondrial disease and dysfunction and abnormalities in 
cerebral folate metabolism are the common associations. Many of these conditions 
can lead to brain damage if inadequately treated. Frye provided a strong argument 
for treating any underlying metabolic disorders, both for ameliorating autism 
and epilepsy [74]. He also added the importance of understanding metabolic and 
genetic biomarkers. If these disorders can be detected early in life or even prena-
tally, treatment can be started at the earliest possible time. Identifying metabolic 
defects might help using standard known or novel treatments in children with 
epilepsy.
These metabolic disorders have diverse classic presentations, so basing 
a diagnostic strategy on the search for one or two specific key symptoms is 
inappropriate.
However, mitochondrial disease is of particular interest in children with ASD 
since it is being increasingly recognized as a cause of epilepsy in individuals with 
ASD [74, 75].
5.3.1 Disorders of energy metabolism
Several disorders affecting energy metabolism have been documented in ASD, 
including mitochondrial disorders and creatine deficiency syndromes. The preva-
lence of mitochondrial abnormalities appears to be very high in ASD [75].
Disorders of creatine metabolism have also been reported in children with ASD 
and epilepsy [76].
The general presentation of children with disorders of creatine metabolism 
includes developmental delay, regression, ASD features, ID, receptive and expres-
sive language disorders, and seizures.
5.3.2 Disorders of cholesterol metabolism
Smith–Lemli–Opitz syndrome (SLOS) is a congenital disorder of cholesterol 
metabolism caused by mutations in both DHCR7 genes. Metabolically, children with 
SLOS demonstrate elevated concentrations of 7-dehydrocholesterol and reduced 
cholesterol concentrations in the blood. Interestingly, 50%–75% of children with 
this disorder meet the criteria for ASD [77]. This disorder is may be associated with 
seizures along with their other clinical presentations [78].
5.3.3 Disorders of vitamin metabolism
These include disorders of folate, pyridoxine, biotin, and carnitine metabolism. 
Children with cerebral folate deficiency (CFD) are commonly diagnosed with 
epilepsy and/or ASD [78].
Since the folate transport system is energy-dependent, a wide variety of mito-
chondrial diseases and novel forms of mitochondrial dysfunction related to ASD 
[79] have been associated with CFD.
Pyridoxine and its active form pyridoxal-5-phosphate play major roles in 
metabolism of glutamic acid to GABA acting as a cofactor. Pyridoxal-5-phosphate 
depletion reduces glutamic acid decarboxylase activity, resulting in a reduction in 
GABA synthesis. In children with ASD, several studies have reported significant 
improvement in behavior and cognition attributable to combined therapy with 
magnesium and pyridoxine [80].
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5.3.4 Disorders of γ-aminobutyric acid metabolism
Succinic semialdehyde dehydrogenase deficiency is a rare disorder of GABA 
metabolism that results from a mutation in both ALDH5A1 genes. Neurological 
manifestations may include seizures, and ASD features among others.
5.3.5 Disorders of pyrimidine and purine metabolism
Children with ASD and comorbid seizures have been described to have disorders 
of purine and pyrimidine metabolism. Patients show a variable combination of 
mental retardation, epilepsy, ASD features, and cerebellar vermis hypoplasia.
5.3.6 Disorders of amino acid metabolism
Disorders in the metabolism of phenylalanine, have been described in children 
with ASD and comorbid epilepsy. Phenylketonuria is an autosomal recessive inborn 
error of phenylalanine metabolism resulting from deficiency of phenylalanine 
hydroxylase secondary to a mutation in the PAH gene on chromosome 12q23.2. 
Children with PKU who go untreated or who do not adhere to the diet adequately 
may demonstrate poor growth, poor skin pigmentation, microcephaly, seizures, 
spasticity, ataxia, aggressive behavior, hyperactivity, ASD features, global devel-
opmental delay, and/or severe intellectual impairment. Recently an inactivating 
mutation in the branched-chain ketoacid dehydrogenase kinase was described to be 
associated with autism, epilepsy, and intellectual disability in three families with 
two children each who were products of first-cousin consanguinity.
5.3.7 Mitochondrial dysfunction associated with epilepsy in ASD
A recent meta-analysis found that 5% of children with ASD met the criteria 
for classic mitochondrial disease, while as many as 30% of children with ASD may 
manifest mitochondrial dysfunction.
Prevalence of abnormal mitochondrial function in immune cells derived from 
children with ASD is exceedingly high.
A meta-analysis found that, overall, 41% of children with ASD and documented 
mitochondrial disease are reported to have seizures.
Mitochondrial dysfunction has also been reported in many genetic syndromes 
associated with ASD and epilepsy. For example, in Rett syndrome, Phelan–
McDermid syndrome, 15q11-q13 duplication syndrome, Angelman syndrome and 
Down syndrome, mitochondrial dysfunction may underlie the phenotype of ASD 
with epilepsy, regardless of the underlying cause.
Abnormalities in mitochondrial function can lead to abnormal development in 
brain circuits, resulting in both neurodevelopmental disorders and epilepsy through 
several mechanisms. Abnormalities in mitochondrial biomarkers have also been 
found in the brains of individuals with ASD. Thus, it is very likely that changes in 
mitochondrial function in the brain affect neural transmission and function in 
children with ASD. Neural synapses that are areas of high energy consumption and 
are especially dependent on mitochondrial function may be one of the mechanisms 
for developing these developmental disorders. Recent studies have suggested that 
oxidative stress may be involved in the development of epilepsy.
Studies have found connection between reactive oxygen species and mitochon-
drial dysfunction in brain tissue from individuals with ASD. This may be another 
mechanism where mitochondrial dysfunction can lead to the development of 
epilepsy in ASD.
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Immune dysfunction is found to be implicated in the development of epilepsy, 
and evidence of cellular and humoral immune dysfunction has also been implicated 
in ASD. Thus, studies suggest abnormalities in immune cell function result in 
seizures in ASD.
Another physiological abnormality that is becoming increasingly recognized in 
both ASD and epilepsy is the dysregulation of calcium [81]. On the other hand, epi-
lepsy may be a common symptom of metabolic disorders and be a clue that a metabolic 
disorder may be the underlying etiology of the neurodevelopmental abnormalities in 
children with epilepsy and ASD. One advantage of investigating and diagnosing meta-
bolic disorders is that treatments for many of these metabolic disorders are available.
6.  Epilepsy syndromes with ASD as frequent neurodevelopmental 
sequelae
Several specific epilepsy syndromes with early onset epilepsy show an autistic 
behavior, some also appear to be the risk factor for later diagnosis of ASD. If they 
are identified appropriately and treated, behavioral improvement which is radical 
in some of the cases can be seen. In these cases, epilepsy originates in the brain 
networks responsible for communication and interactions. These include infantile 
spasms and Lennox–Gastaut syndrome. More recently, clinical overlap has been 
observed in cases with continuous slow waves during sleep (CSWS) and Landau–
Kleffner syndrome and ASD [82].
6.1 West syndrome (WS)
WS is an epileptic encephalopathy characterized by infantile spasm/epileptic 
spasms, an EEG pattern of hypsarrhythmia and cognitive stagnation or regression. 
They usually occur before 2 years of age. Genetic causes are present in many of 
them and abnormalities in several brain developmental pathways are noted.
ASD may develop in a few of them. However, an association between TSC and 
duplications of FOXG1 have been reported consistently.
6.2 Lennox–Gastaut syndrome (LGS)
LGS is a childhood-onset epilepsy, which is characterized by constellation of 
several distinct types of seizures and electroclinical features of diffuse slow spike 
waves and generalized paroxysmal fast activity in sleep. Prevalence of ASD in LGS 
is rare, although ASD has been reported in patient with LGS resulting from duplica-
tions of maternal 15q11q13 [83].
6.3  Landau–Kleffner syndrome (LKS)/continuous spikes and slow waves 
during slow sleep (CSWS)
LKS is an epilepsy-aphasia syndrome that is characterized by regression in 
language and characteristic CSWS on EEG-termed as electrical status epilepticus of 
slow sleep (ESES). Several children who had been diagnosed with ASD were noted 
to have a predominant language deficit. Stereotypies and withdrawal are also com-
mon in LKS, but whether these children also have deficits in social reciprocity is not 
clear. The association may be more related to severe receptive language deficit. Copy 
number variants have been detected in patients with LKS who also have associated 
ASD [84], and, most recently, GRIN2A mutation have been identified in patients 
with epilepsy-aphasia phenotypes [85].
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7. Regression in Autism
Developmental regression is present in approximately one-third of children 
with ASD [86] and is believed to have an association with epilepsy. The relationship 
between regression and epilepsy in ASD has therefore long been of interest because 
of the hope that some developmental regression in idiopathic ASD could be caused 
by epilepsy and be reversible through using anti-seizure therapies [87].
The overlap of language and autistic regression to epilepsy, EEG epileptiform 
activity, sleep, and to epileptic encephalopathies such as LKS continue to be 
controversial areas of research and of clinical interest because of the close clinical 
resemblance to autism.
LKS or acquired epileptic aphasia may present as a developmental language 
regression followed by autistic-like social-communicative phenotype. LKS usually 
presents between 3 and 7 years of age with loss of language skill in children who 
were previously normal and most but not all affected children have convulsive 
seizures. In case on early LKS, it becomes difficult to differentiate it from ASD 
clinically and the diagnosis is done mainly on EEG finding and response to anti-
seizure treatment. The EEG in the awakened state often has a normal background 
with seizures of various types in LKS. During sleep, it is characterized by epileptic 
discharges throughout the sleep-electrical status epilepticus (ESES) on EEG that 
may affect cognitive processing. In children with autistic regression, both language 
and behavior in association with significant social deficits occur between 18 and 
24 months compared to usually only language regression in LKS, which is more 
dramatic and the social deficits are less severe than those with autism [88]. McVicar 
et al. in their study reported that children with isolated language regression have a 
higher frequency of epileptiform discharges and seizures than children with both 
language and autistic (i.e., social and behavioral) regression [89].
An extensive review, in 2002 on epileptiform neurocognitive disorders linked 
with speech/language deterioration concluded that “acquired epileptiform aphasia 
(AEA) can be conceptualized on a spectrum with other epileptiform neurocognitive 
disorders that may share pathophysiological features”. They also added that “with-
out better documentation of potential factors around the time of the regression, it 
will be difficult to identify the fundamental factors that differentiate these condi-
tions, their response to treatment and long-term prognosis” [90].
CSWS, an epileptic syndrome of that is associated with EEG pattern of ESES 
may present with regression in global skills that overlaps with autism [91]. However, 
the differences in age of regression, type of regression, frequency of epilepsy and 
EEG abnormalities suggest that these are distinct phenotypes.
Nonconvulsive status epilepticus (NCSE) may also have features that have a 
strong similarity to autism. The child may exhibit poor reciprocal social interac-
tion, poor verbal and nonverbal communication. But with effective treatment, the 
features of autism disappear.
Magnetoencephalography has identified precise location of the source of these 
epileptic EEG discharges. The finding from this investigation shows that focal spike 
waves (FSW) in the perisylvian region and located in the superior temporal gyrus 
may cause auditory and verbal agnosia (LKS). When FSW predominate in the 
prefrontal regions, a cognitive regression with features of CSWS, when in cortical 
areas like the superior temporal sulcus or the fusiform gyrus involving the networks 
relating emotions to higher-level visual representations could interfere with the 
developing capacity to recognize the emotional signals of faces, that are typically 
deficient in autism.
Other epileptic disorders, like refractory partial epilepsies of frontal or temporal 
origin like the Benign epilepsy with centrotemporal spikes (BECTS)also interfere 
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with developing language networks and/or other circuits involving the “social 
brain” such as the amygdala, cingulate and orbitofrontal cortex and account or 
contribute to language and autistic regression. Other examples are Focal dysplasias, 
hippocampal sclerosis, congenital tumors or tuberous sclerosis and hypothalamic 
hamartomas.
In addition, an increasing number of genetic and metabolic encephalopathies 
with severe developmental problems are now recognized with autistic regression 
where epilepsy may aggravate the regression.
It is also found that approximately 20% of children with autistic regression 
without epilepsy may have an abnormal EEG, the majority with spikes or spike-
and-wave discharges [92]. Although this abnormal EEG is found usually after the 
regression, there is no evidence of a causal relationship between the epileptiform 
abnormalities and the regression [93].
Figure 4 shows EEG of LKS in awake and CSWS in sleep with ESES.
8. Autism in epilepsy
A meta-analysis of 19 studies showed a pooled ASD prevalence of 6.3% in indi-
viduals with epilepsy, which is considerably higher than the reported prevalence 
of 0.75% to 1.1% in the general population [94]. Tuchman et al. reported approxi-
mately 30% of children with epilepsy have autism and/or intellectual or develop-
mental disabilities [95]. Several studies have shown that children with epilepsy have 
an increased risk of being diagnosed with ASD [8, 16, 22]. A higher prevalence was 
found for studies with younger age groups, ID, and specific epilepsy syndromes 
(West syndrome, Dravet syndrome).
Epilepsy and autism both can arise from abnormal excitability and disrupted 
synaptic plasticity in the developing brain. This abnormal plasticity can also result 
from genetic conditions.
Early-life seizures can produce a variety of cellular and molecular changes 
in the hippocampus, including short-term enhancement of excitation and long-
term enhancement of inhibitory neurotransmission and reductions in excitatory 
Figure 4. 
Electroencephalogram finding of a (A) 4 years 6 months old boy with LKS, and regression of speech for one 
year showing spike and waves over frontal central and temporal regions (B) 7 year old girl with regression of 
speech and cognitive function in a case of CSWS showing ESES, generalized spike waves in all the channels.
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neurotransmission [35]. All these early seizures also have numerous disruptive 
effects on neural development, including abnormal synaptic reorganization, and 
cortical interneuron dysfunction [96, 97]. This in turn disrupts the construction 
of cortical networks necessary for acquiring certain skills during development, 
and may predispose an individual towards developing ASD [15]. Further, risk of 
both epilepsy and ASD is elevated in numerous genetic disorders as mentioned 
previously, such as Rett syndrome, fragile X syndrome, and tuberous sclerosis 
complex [37].
Lukmaji et al. emphasized the importance of screening for autism in persons 
with epilepsy, and vice versa, to appropriately tailor treatment decisions and 
improve patient outcomes [28]. As in their systematic review revealed the occur-
rence of autism in persons with epilepsy and epilepsy in persons with autism to 
be higher than the previously reported independent occurrence of each of these 
conditions in the general population.
9. EEG abnormalities
ASD are associated with increased incidence of EEG abnormalities. EEG epi-
leptiform abnormalities were found at a range of 35% to 86% in ASD individuals 
with epilepsy [9, 21, 98] and up to 28.6% [21] to 60% [9] in individuals without 
epilepsy. These discharges are often more common when there is history of autistic 
regression, even if there is no history of seizures or epilepsy [99]. In addition to 
epileptiform discharges, non-epileptiform discharges were also found in ASD, these 
were- disorganized and slowing of background rhythm, asymmetry etc. [100]. But 
epileptiform EEGs seemed to be more common than nonepileptiform abnormalities 
in most of the studies [101–105].
Abnormal EEG is considered as a biomarker of cortical dysfunction [8, 100] and 
provide evidence that autism is a neurobiological disorder [106]. Interictal dis-
charges are thought to interfere with normal neural processing which may further 
impair cognitive function [17, 18, 100]. The clinical importance of epileptiform 
discharges without overt seizures are not clear, but they may also cause behavioral 
and cognitive problems [99].
EEG should be considered in children with clinical or suspected seizures and, 
in all the children where autism is questionable and a clinical suspicion of LKS 
is present. Performing a sleep-EEG was highly recommended by Pacheva et al. 
in all patients to prevent underdiagnosis of ESES and LKS [21]. The authors also 
mentioned the need of timely treatment to get improved behavior and cognition 
in patients with ESES. Fernandez et al. also concluded in that a treatment trial 
with AED is justified in patients with epileptic encephalopathies and cognitive 
dysfunction/regression, that could be related to epileptiform discharges [107]. 
Children with LKS may also have an autistic-like regression that extends to 
behaviors beyond language [87]. Presence of epileptiform EEG abnormalities 
even in the absence of clinical seizure found in LKS and ESES is a controversial 
problem [108, 109].
10. Management of individuals with both epilepsy and autism
Both the conditions should be managed individually. This depends upon the 
causes if present, especially in case of epilepsy. First of all, the cause of epilepsy in 
autism should be investigated appropriately. It has to be ensured that the autistic 
features are not the result of ESES or frequent epileptiform discharges [110].
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The diagnosis of epilepsy become more difficult in autism, especially if there is 
accompanying intellectual disability because history taking in these cases becomes 
more difficult.
The treatment of epilepsy in ASD is based on the general principles of treatment 
of epileptic seizures with traditional antiepileptic drugs (AEDs). Usually, valproate, 
lamotrigine and levetiracetam are used as the most effective and tolerable AEDs 
for individuals with ASD [74]. But levetiracetam can have negative effects on mood 
and behavior and be associated with deterioration in children, whereas lamotrigine 
tends to be a mood-leveling antiepileptic drug and Topiramate can be associated 
with word-finding difficulties [110].
The discovery of the role of neuronal autoantibodies has been one of the most 
exciting developments in the recent years. These antibodies can result in seizures, 
loss of skills, (sometimes a dramatic loss), behavioral changes and even psychosis. 
Effective immunotherapy can, in at least some cases, reverse all these changes 
[111, 112]. This is an area which requires further consideration.
New therapeutic options were suggested for ASD and epilepsy, based on the 
opinion that gene defects could determine all the symptoms of these disorders. 
This also includes modulators of GABA A receptors, GABA agonists, modulators 
of GABA metabolism, glutamate receptor antagonists, insulin-like growth factor 1 
and m-TOR inhibitors for ASD-epilepsy comorbidity [113]. M-TOR inhibitors like 
Everolimus (Rapamycin) and Sirolimus have positive results in patients with TSC, 
ASD and PTEN-related disorders. After treatment with conventional GABAnergic 
agonists, a paradoxical result was reported in ASD [101]. In addition, ASD with 
epilepsy having 15q11.2 duplication, effectiveness of benzodiazepines was reported 
to be lowered [114].
In addition to the treatment, the usual management of autism should be 
continued.
10.1  Management of additional comorbidities in the presence of both epilepsy 
and autism
10.1.1 Attention deficit hyperactivity disorder
ADHD is common in children with autism and in children and adolescent with 
epilepsy. Diagnosing ADHD in epilepsy sometimes becomes difficult, because some 
of the children with epilepsy present with features of ADHD. This is due to frequent 
epileptiform discharge. In those cases, treating these epileptic discharges with 
AEDs will alleviate these symptoms. Few children with epilepsy may have inatten-
tion, hyperactivity and distractibility as a result of antiepileptic medication, as for 
example, treatment with phenobarbitone, benzodiazepine or vigabatrin [110]. So, 
review of antiepilepetic medication is very important before diagnosing the child as 
having ADHD.
Epilepsy is a highly variable condition and after treatment with AED, there 
might be is no change in seizure or even there is high frequency of seizure and since 
ADHD medication is started, it may be incorrectly concluded that this increase in 
seizures is because of the ADHD treatment.
There are two groups of medication currently used to treat ADHD: stimulants 
(methylphenidate, amphetamine) and non-stimulants (Atomoxetine, alpha-2 
agonists). When children with symptoms of ADHD require medication, current 
guidelines recommend starting with a trial of a stimulant like methylphenidate. If 
this first stimulant does not prove to be effective, the alternative stimulant is then 
used [115]. If stimulants are not effective or cause intolerable adverse effects, then 
nonstimulants like atomoxetine, alpha-2 agonists, and antidepressants are used.
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Methylphenidate is the most commonly used medicine for ADHD. Large obser-
vational studies conducted in children and adolescents with epilepsy have found 
that ADHD medications in general and stimulants like methylphenidate are not 
associated with increased risk of seizures [116]. Use of low and moderate doses of 
methylphenidate has been observed in reduction of seizure frequency and severity 
along with improved quality of life in a Brazilian study done in 2015 [117]. However, 
it is important to monitor seizure frequency in the first few weeks and months after 
prescribing methylphenidate [116] as there are still questions regarding use of this 
drug in epilepsy.
Guidance for identification and treatment of individuals with attention 
deficit/hyperactivity disorder and ASD based upon expert consensus in the 
UK in 2020 [118] emphasized on non-pharmacological interventions and care 
management, including psychoeducation, carer interventions, behavioral/envi-
ronmental and Cognitive Behavioral Therapy (CBT) approaches and educational 
interventions, followed by pharmacological treatments. They have commented 
that in children, pharmacological intervention should be preceded by behavioral 
observation and psychological intervention as the first-line treatment. And if 
psychological/environmental interventions fail in children, then ADHD medica-
tion may be helpful for treating symptoms of inattention. Medication should be 
used in a ‘low and slow’ approach as people with both ADHD with epilepsy may 
be more treatment resistant and more prone to develop side effects to medication. 
Medication should be given for the shortest time possible and side effects should 
be monitored carefully.
Researchers also mentioned about the relative little evidence, on using other 
ADHD treatments, such as atomoxetine, guanfacine and clonidine in children with 
autism, having both epilepsy and ADHD [110]. However, several research papers 
and reviews found no clear evidence about exacerbation of seizures with these 
medications. Besag et al., in their paper summarized, about 30% of children with 
epilepsy had ADHD and about 70% among those with epilepsy and ADHD ben-
efited from treatment of their ADHD symptoms with methylphenidate [119].
10.1.2 Anxiety
Anxiety is commonly found in young people with autism and epilepsy. Children 
with epilepsy with co-morbid psychiatric disorders like — ADHD, depression, and 
anxiety disorders, end up with significant compromise in academic performance 
and social skills, leading to deterioration in the Quality of life [120].
Risperidone and Aripiprazole in low dose can improve the behavior in children 
with autism. The mechanism is probably through decreasing anxiety. But the dose 
used should be very low because of the risk of seizure exacerbation with high doses 
of these antipsychotic drugs. On the other hand, the antiepileptic drugs like car-
bamazepine, phenobarbital and phenytoin may decrease the blood levels of anti-
psychotic drugs and a larger dose of antipsychotics may be required who are taking 
these AEDs. The management goals in pediatric epilepsy with anxiety disorders 
are — adequate seizure control, optimization of the functioning of the child and 
keeping the patient in best and simple pharmaco-therapeutic regimen [121].
The clinician should avoid an antiepileptic drug which is having side effects like 
behavioral problems.
Behavioral therapy should be the first-line approach to managing anxiety. 
Despite the effectiveness of selective serotonin reuptake inhibitors in decreas-
ing anxiety in adults and teenagers there is a lack of evidence for a beneficial 
role of these drugs in treating anxiety in children with autism, according to a 
Cochrane review.
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10.1.3 Sleep
Sleep disturbances are very common in children with autism. Epilepsy and sleep 
have reciprocal relationships. In some of the cases, sleep facilitates seizures and, in 
some seizures, adversely affects sleep architecture. If sleep problems are present, 
possibility of nocturnal seizures should it is eliminated. In that case careful history 
and if required antiepileptic medication should be tried. And if the sleep distur-
bance is not due to nocturnal seizures, melatonin is the drug of choice [110]. There 
is no good evidence of exacerbating seizures using melatonin. Animal work suggests 
that melatonin might have an antiepileptic effect. Identification and management of 
sleep disorders may improve seizure control and challenging behaviors of autism
11. Future direction
No single unifying ASD–epilepsy phenotype is there till now but understand-
ing possible commonalities in subgroups of children with an ASD– epilepsy 
phenotype should help us in understanding the pathophysiology of both ASD and 
epilepsy [110].
Prospective, population-based studies are recommended, whenever there is any 
history of regression [110]. These studies should include investigations like genetic 
and chromosomal studies, searching for metabolic/mitochondrial disorders, EEG 
including sleep EEG and also testing for possible neuronal antibodies.
Environmental factors, prenatal factors such as maternal exposure to infection, 
toxic chemicals, pollution, alcohol and drugs should be searched for as these are the 
risk factors of autism and they might also cause epilepsy. A history of exposure to 
antiepileptic drugs like maternal valproate and learning problems/probable autism 
in the offspring and thorough obstetric and neonatal factors should also be an 
essential part of the history-taking.
12. Conclusions
Epilepsy is a common co-occurrence in children and persons with ASD. 
Determining the bidirectional prevalence of autism and epilepsy is important. 
Understanding the specific effects of the genes/metabolic/environmental pathways 
affected may give a better insight into the pathogenesis of the developmental 
problems. ID is also an important association in epilepsy and ASD. Multiple inter-
related factors are there in the pathogenesis of ASD-epilepsy connection. Further, 
understanding these comorbidities will have a profound effect on the management 
of these challenging patient populations. For example, it has been found that 
autistic symptoms can be minimized when epilepsy is being treated in patients with 
both the conditions. Well-managed epilepsy, autism, and associated comorbidities 
can significantly improve the quality of life in both patient and caregiver. Further 
population-based studies and investigations including genetic, and, metabolic, in 
addition to EEG are needed, especially in case of regression in order to detect both 
these conditions in the early years of life.
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